Status:
COMPLETED
Exploration of the Potential Mechanisms of n-3 Fatty Acids Supplementation in Depression and Cognitive Function in Patients With Late-life Depression
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Late Life Depression
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
Depression in the elderly causes considerable distress, disability, and loss of life. The accelerating aging boom is accentuating the importance of addressing late life depression (LLD). Extensive eff...
Detailed Description
Depression in the elderly causes considerable distress, disability, and loss of life. The accelerating aging boom is accentuating the importance of addressing late life depression (LLD).Extensive effo...
Eligibility Criteria
Inclusion
- Age \> 60 years.
- Previous major depressive disorder (MDD), single or recurrent.
- Mood is relatively stable for at least 3 weeks and the score of 17-item Hamilton Depression Rating Scale (HAMD-17) less than 10
Exclusion
- Inability to provide informed consent.
- Depressive symptoms severe enough (i.e., HAMD-17 \>= 10) at the baseline.
- Dementia, as defined by MMSE \< 24 and clinical evidence of dementia.
- Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms.
- Abuse of or dependence on alcohol or other substances within the past 3 months, and confirmed by study physician interview.
- High risk for suicide (e.g., active SI and/or current/recent intent or plan) AND unable to be managed safely in the clinical trial (e.g., unwilling to be hospitalized). Urgent psychiatric referral will be made in these cases.
- Non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).
- Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. This will be determined based on information from the patient's personal physician and study physician's clinical judgment.
Key Trial Info
Start Date :
September 25 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 25 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05972798
Start Date
September 25 2018
End Date
December 25 2020
Last Update
August 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Che-min Lin
Keelung, Taiwan